Zylox-Tonbridge and GL Capital Announce Strategic Investment in LifeTech Scientific to Build a Leading Vascular and Structural Heart Intervention Platform

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

ZYLOX-TONBRIDGE

More Like This

Zylox-Tonbridge Announces 2025 Interim Results: Strong Revenue Growth with Net Profit Surging Over 76% Year-over-Year

Zylox-Tonbridge to Acquire Equity Interest in A European Medical Device Company to Accelerate Expansion in the Global MedTech Market

PR Newswire associated0

Zylox-Tonbridge Recognized as Most Honored Company in Extel 2026 Asia Executive Team Survey

PR Newswire associated0

Zylox-Tonbridge Delivers Strong First-Half 2026 Results as International Revenue Surges 349%

Leading Chinese Innovative Medical Device Maker Insight Lifetech Has Successfully Listed on STAR Market

Technology Holdings Launches TH Healthcare & Life Sciences: Revolutionizing the Healthcare Investment Banking Landscape, leveraging over two decades of Healthcare Investment Banking transaction experience

Venus Medtech's Exciting Innovations for Structural Heart to Be Showcased at London Valves 2023

LifeArc Ventures 2024: new investments, targeted follow-ons and substantive portfolio progress